Barclays’s Cellectar Biosciences CLRB Stock Holding History

Barclays’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,017	Closed	-$258K	–	5300
2024 Q3	$258K	Sell	4,017 -1,723	-30%	-$114K	﹤0.01%	4162
2024 Q2	$430K	Sell	5,740 -5,533	-49%	-$531K	﹤0.01%	3130
2024 Q1	$1.35M	Buy	+11,273	New	+$1.22M	﹤0.01%	2889
2021 Q2	–	Sell	-1	Closed	-$1K	–	4891
2021 Q1	$1K	Buy	+1	New	+$595	﹤0.01%	4583

Other funds holding CLRB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's CLRB Position: Q4 2024 in Review

Barclays sold out of Cellectar Biosciences (CLRB) in Q4 2024, closing a stake of 4,017 shares — an estimated $258K sold.

Barclays first reported a position in CLRB in Q1 2021 and held it in 4 quarters. The position peaked at $1.35M in Q1 2024. 30 funds tracked by Wall St. Rank hold CLRB as of Q4 2024.

Barclays reported no remaining Cellectar Biosciences position as of Q4 2024 after selling out during the quarter.
Barclays sold 4,017 Cellectar Biosciences shares in Q4 2024, an estimated $258K.
Barclays first reported a position in Cellectar Biosciences in Q1 2021 and held it in 4 quarters.
Barclays's Cellectar Biosciences position peaked at $1.35M in Q1 2024.
30 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2024.

Based on Barclays's 13F filing for Q4 2024, filed 13 Feb 2025.